Breaking news

Cyprus: The Promising Pathway For Energy Investments

Energy Minister George Papanastasiou recently emphasized Cyprus as a burgeoning hub for energy investments. Speaking at the Capital Link Cyprus business forum in New York, Papanastasiou highlighted the island’s strategic location, which is nestled close to Africa and the Middle East, while also being a member of the European Union.

International ratings agencies have bolstered Cyprus’ credibility with recent credit rating upgrades. According to Papanastasiou, such enhancements in financial stature make Cyprus difficult to overlook on the global stage.

While the natural gas reserve in Cyprus’ exclusive economic zone (EEZ) holds great promise, Papanastasiou pointed out infrastructure as the current bottleneck. Efforts are underway to mitigate energy costs and maximize the potential wealth from these reserves. Recent agreements with Egypt further fortify these ambitions, positioning Egypt as a ‘host government’ to refine and transport natural gas efficiently.

Cyprus is also at the forefront of the ambitious Great Sea Interconnector project, which aims to link Cyprus, Greece, and Israel’s electricity grids. Despite geopolitical risks and recent disruptions by Turkish warships, international interest remains robust. The government’s pending decision on financial contributions may shape the project’s future and underscores the urgency highlighted by Greek Energy Minister Theodoros Skylakakis.

As the Mediterranean island ventures into new agreements and collaborative projects, it simultaneously monitors a volatile global trade landscape.

Medochemie And Theramir Announce Strategic Investment Agreement To Advance Biotech Manufacturing In Cyprus

Pharmaceutical manufacturer Medochemie and biotechnology company Theramir, both Cyprus-based, have announced a strategic investment agreement and collaboration aimed at developing next-generation biological therapies and expanding manufacturing capabilities in Cyprus.

The agreement, announced on 2 September 2026, brings together Medochemie’s experience in pharmaceutical manufacturing and Theramir’s biotechnology research. The companies said the collaboration would support advanced pharmaceutical manufacturing in Cyprus and south-eastern Europe.

What The Partnership Covers

Medochemie’s contribution will include its expertise in manufacturing sterile therapeutic products and its access to international markets.

Theramir develops technologies based on extracellular vesicles and microRNAs. Its work includes using stem-cell-derived extracellular vesicles to deliver microRNAs, small, non-coding RNA molecules that regulate genes and biological pathways associated with cancer growth and metastasis.

Under the agreement, the companies will jointly support the development of “Good Manufacturing Practice” capabilities for next-generation biological therapies. The partnership is also intended to help move these therapies towards clinical development.

A Wider Role For Cyprus

The collaboration will also support Theramir’s wider research programme. According to the companies, it is intended to strengthen Cyprus’s biotechnology infrastructure and expand local capacity in next-generation biomanufacturing.

They present the agreement as a step towards giving Cyprus a larger role in biotechnology and advanced pharmaceutical manufacturing for south-eastern Europe and international markets.

The Future Forbes Realty Global Properties
Uol
Aretilaw firm
eCredo

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter